The PDUFA date of June 29, 2026 for OLC remains the primary catalyst. The slight EPS beat and strong cash position reduce near-term financing risk. Traders should monitor FDA advisory committee announcements or any pre-PDUFA communication.
Price Chart
Executive Summary
Unicycive Therapeutics reported Q1 2026 results with an EPS of -$0.54, slightly beating the consensus of -$0.55. The company maintains a strong cash position of $57.1M, funding operations into 2027, while the PDUFA target action date for OLC remains June 29, 2026. No material changes to the business outlook or guidance were provided.
Key Financial Metrics
Key Facts
- Net loss per share (basic and diluted) for Q1 2026: $(0.54), vs consensus $(0.55) — slight beat
- Cash, cash equivalents, and marketable securities: $57.1M as of May 11, 2026
- PDUFA target action date for OLC NDA resubmission: June 29, 2026
- R&D expenses decreased to $1.6M from $2.2M YoY; G&A increased to $6.8M from $5.8M
Financial Impact
EPS of -$0.54 vs -$0.55 consensus, a slight beat. Cash position of $57.1M provides runway into 2027.
Risk Factors
- FDA non-approval of OLC would eliminate near-term catalyst and likely lead to significant stock decline
- Dilution risk if additional financing is needed before potential OLC launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-054736 |
| Document: ea0290277-8k_unicycive.htm | 0001213900-26-054736 |
| Document: 0001213900-26-054736-index-headers.html | 0001213900-26-054736 |
| Document: 0001213900-26-054736-index.html | 0001213900-26-054736 |
| Document: 0001213900-26-054736.txt | 0001213900-26-054736 |
| 8-K Data (Synthetic) | 0001213900-26-054736 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 3 | $4.22 | awaiting T+60 | — | $3.58 (−15.17%) |
Sep 29, 2026 27d ago | 8-K | $4.55 | awaiting T+60 | — | $3.58 (−21.32%) |
Aug 12, 2026 10w ago | 8-K | $5.39 | awaiting T+60 | — | $3.58 (−33.58%) |
Jul 2, 2026 16w ago | 8-K | $5.73 $4.81 | ▼ −16.06% | ▼ −19.06% | $3.58 (−37.52%) |
Jun 22, 2026 18w ago | DEFA14A | $7.87 $4.71 | ▼ −40.15% | ▼ −41.90% | $3.58 (−54.51%) |
Jun 16, 2026 18w ago | EFFECT | $7.17 $5.31 | ▲ +25.94% | ▲ +26.94% | $3.58 (+50.07%) |
Jun 5, 2026 20w ago | S-3 | $6.66 $5.05 | ▲ +24.17% | ▲ +27.23% | $3.58 (+46.25%) |
May 12, 2026 23w ago | 8-K | $8.17 $5.05 | ▼ −38.19% | ▼ −42.57% | $3.58 (−56.18%) |
May 12, 2026 23w ago | Press Release | $8.17 $5.05 | ▲ +38.19% | ▲ +42.57% | $3.58 (+56.18%) |
Apr 6, 2026 29w ago | 8-K | $6.62 $5.28 | ▼ −20.24% | ▼ −33.71% | $3.58 (−45.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers